
Lexaria Bioscience ( ($LEXX) ) has provided an update. Lexaria Bioscience has entered an agreement with an unnamed pharmaceutical company to evaluate one or more proprietary molecules processed with its
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LEXX | Lexaria Bioscience | 4.28 | -12.22 | -74.06% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.28 | -74.06% |

Lexaria Bioscience ( ($LEXX) ) has provided an update. Lexaria Bioscience has entered an agreement with an unnamed pharmaceutical company to evaluate one or more proprietary molecules processed with its

Lexaria Bioscience (LEXX) announces that it has entered into an Agreement with an unnamed pharmaceutical company to investigate Lexaria’s DehydraTECH technology with one or more proprietary PharmCo molecules. Today’s announcement

Lexaria Bioscience (LEXX) provides this update on additional new intellectual property granted to the Company as a result of its ongoing research and development, R&D, programs. The expansion of our

Lexaria Bioscience (LEXX) reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 which is evaluating two oral DehydraTECH-semaglutide compositions against Novo’s commercially

An announcement from Lexaria Bioscience ( ($LEXX) ) is now available. Lexaria reported new animal study data showing multiple enhanced DehydraTECH-CBD formulations that matched or exceeded one of its best

Lexaria Bioscience (LEXX) provides the following results from animal study GLP-1-A26-1 that evaluated a number of formulation enhancements using both DehydraTECH-CBD compositions and DehydraTECH-semaglutide glucagon-like peptide-1 compositions to explore the

An announcement from Lexaria Bioscience ( ($LEXX) ) is now available. Lexaria Bioscience is intensifying its strategic focus on the fast-growing GLP-1 weight-loss and diabetes drug market, positioning its DehydraTECH

This filing relates to the offer and sale from time to time by the selling stockholders of up to 923,827 shares of common stock. The company is not selling any

Lexaria Bioscience ( ($LEXX) ) has issued an announcement. Lexaria Bioscience has strengthened its financial position with US$7.9 million in new capital from an Australian tax refund and a recent

Lexaria Bioscience (LEXX) said it is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at $12.92/share. The combined net proceeds
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Dec 26, 2025 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.